Incannex Healthcare (IXHL) EBITDA Margin (2024)
Incannex Healthcare (IXHL) posted quarterly EBITDA Margin of 41700.0% for Q4 2024, down 393.41% on a QoQ basis from 8451.35% in Q3 2024.
Incannex Healthcare (IXHL) EBITDA Margin (2024) Analysis & Trends
Incannex Healthcare (IXHL) has reported EBITDA Margin for 1 consecutive years, with 41700.0% the latest figure, recorded in Q4 2024.
- Quarterly EBITDA Margin changed N/A year-over-year to 41700.0% in Q4 2024, while the trailing twelve-month figure through Jun 2025 was 27661.63% (changed N/A YoY) and the FY2025 annual result came in at 27661.63%, up 22268004.0% from the prior year.
- EBITDA Margin declined to 41700.0% in Q4 2024 per IXHL's latest filing, from 8451.35% in the prior quarter.
- Over the last five years, EBITDA Margin for IXHL reached as high as 8451.35% in Q3 2024 and fell as low as 41700.0% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Incannex Healthcare | 3.63 Mn | 3.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -41,700.00% |
| Sep 30, 2024 | -8,451.35% |